Understanding the evolution of coverage policies for prophylaxis treatments of hemophilia A without inhibitors: a payer Delphi panel

BACKGROUND: The landscape for hemophilia A prophylaxis is rapidly expanding from factor VIII replacement therapy to include novel treatments such as nonfactor replacement therapies that may enhance coagulation (e.g., emicizumab) or inhibit anticoagulant pathways (e.g., fitusiran and concizumab). For...

Descripción completa

Detalles Bibliográficos
Autores principales: Graf, Marlon, Tuly, Rifat, Harley, Carolyn, Pednekar, Priti, Batt, Katharine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394196/
https://www.ncbi.nlm.nih.gov/pubmed/33843253
http://dx.doi.org/10.18553/jmcp.2021.20600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394196/
https://www.ncbi.nlm.nih.gov/pubmed/33843253
http://dx.doi.org/10.18553/jmcp.2021.20600

Ejemplares similares